Clinical Research Directory
Browse clinical research sites, groups, and studies.
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
Sponsor: Centre Oscar Lambret
Summary
This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
Official title: Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC): A Cohort Study
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2020-09-08
Completion Date
2026-06
Last Updated
2026-03-17
Healthy Volunteers
No
Conditions
Interventions
specimen sample collection
Before and during treatment, and at progression, collection of : * Blood * Exhaled air * Saliva * Sweat * Tears * Urine
Locations (1)
Centre Oscar Lambret
Lille, France, France